BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 17197919)

  • 1. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
    Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
    Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation.
    Wang KL; Yang Q; Cleary KR; Swisher SG; Correa AM; Komaki R; Ajani JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Oct; 107(7):1467-74. PubMed ID: 16955509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.
    Chirieac LR; Swisher SG; Ajani JA; Komaki RR; Correa AM; Morris JS; Roth JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2005 Apr; 103(7):1347-55. PubMed ID: 15719440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor.
    Tong DK; Law S; Kwong DL; Chan KW; Lam AK; Wong KH
    Ann Surg Oncol; 2010 Aug; 17(8):2184-92. PubMed ID: 20217248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
    Chirieac LR; Swisher SG; Correa AM; Ajani JA; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Clin Cancer Res; 2005 Mar; 11(6):2229-36. PubMed ID: 15788671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
    Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
    Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer.
    Chang EY; Smith CA; Corless CL; Thomas CR; Hunter JG; Jobe BA
    Am J Surg; 2007 May; 193(5):614-7; discussion 617. PubMed ID: 17434367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
    Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer.
    Ruol A; Portale G; Castoro C; Merigliano S; Cagol M; Cavallin F; Chiarion Sileni V; Corti L; Rampado S; Costantini M; Ancona E
    Ann Surg Oncol; 2007 Nov; 14(11):3243-50. PubMed ID: 17713823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
    Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
    Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus.
    Rohatgi PR; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh G; Vaporciyan A; Lynch PM; Rice DC; Roth JA; Ajani JA
    Cancer; 2005 Oct; 104(7):1349-55. PubMed ID: 16130133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years.
    Internullo E; Moons J; Nafteux P; Coosemans W; Decker G; De Leyn P; Van Raemdonck D; Lerut T
    Eur J Cardiothorac Surg; 2008 Jun; 33(6):1096-104. PubMed ID: 18407509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?].
    Hölscher AH; Metzger R; Schneider PM
    Zentralbl Chir; 2000; 125(4):319-25. PubMed ID: 10829311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current diagnosis and therapy of esophageal carcinoma].
    Mühr-Wilkenshoff F; Stahl M; Faiss S; Zeitz M; Scherübl H
    Z Gastroenterol; 2004 Jul; 42(7):615-21. PubMed ID: 15248111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard.
    Donohoe CL; O'Farrell NJ; Grant T; King S; Clarke L; Muldoon C; Reynolds JV
    Ann Surg; 2013 Nov; 258(5):784-92; discussion 792. PubMed ID: 24045450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.